Tesaro reports Phase II data for Zejula in biomarker-selected ovarian cancer patient population

Tesaro Inc. (NASDAQ:TSRO) reported data from 51 evaluable PARP inhibitor-naïve patients with homologous recombination deficiency (HRD)-positive, platinum-sensitive ovarian cancer

Read the full 199 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE